Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis

Gastroenterol Hepatol. 2021 Feb;44(2):156-157. doi: 10.1016/j.gastrohep.2020.07.020. Epub 2020 Nov 14.
[Article in English, Spanish]
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use
  • Colitis, Ulcerative / drug therapy*
  • Drug Therapy, Combination
  • Female
  • Fingolimod Hydrochloride / administration & dosage
  • Fingolimod Hydrochloride / therapeutic use*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • JC Virus / isolation & purification
  • Leukapheresis
  • Leukoencephalopathy, Progressive Multifocal / complications
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / etiology
  • Remission Induction
  • Sphingosine-1-Phosphate Receptors / drug effects
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Virus Activation

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Sphingosine-1-Phosphate Receptors
  • Tumor Necrosis Factor-alpha
  • golimumab
  • Fingolimod Hydrochloride
  • Methylprednisolone